Our results suggest that clinicians need to carefully weigh the long-term risks and benefits of exposure to androgen deprivation therapy, particularly in patients with a long life expectancy or patients who already show signs of cognitive decline.
According to large-scale trials and the respective guidelines, clopidogrel is the recommended P2Y12 inhibitor in stable patients, while prasugrel and ticagrelor are recommended, in the absence of contraindications, in patients with ACS.
This study lends support to the EBV hypothesis in Multiple Sclerosis and suggests that a T cell immunotherapy targeting EBV infected B lymphocytes and plasma cells may be safe and have a positive effect on disease activity.
Ashani Weeraratna, Ph.D.
The Ira Brind professor and
Co-program leader of the Immunology, Microenvironment and Metastasis Program
The Wistar Institute
Member of Wistar’s Melanoma Research Center
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This study shows for the first time that older patients, especially those who have had prior MAPKi therapy fare better than younger patients when treated with anti-PD1. We found that tumors in younger patients and younger mice have higher levels of Tregulatory cells, the cells that regulate other immune cells. This is not true systemically, only within the tumor microenvironment.
We were surprised because we expected that, as with targeted therapy, older patients would have a poorer response to immunotherapy, given what we perceive as a poorer immune system in older patients.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.